99 related articles for article (PubMed ID: 2177066)
21. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
Ujiie T
Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
[TBL] [Abstract][Full Text] [Related]
22. Sensitization of P388 murine leukemia cells to hydroxyurea cytotoxicity by hydrophobic iron-chelating agents.
Satyamoorthy K; Chitnis M; Basrur V
Anticancer Res; 1986; 6(2):329-33. PubMed ID: 3518597
[TBL] [Abstract][Full Text] [Related]
23. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Guo QL; Wu MS; Chen Z
Acta Pharmacol Sin; 2002 Oct; 23(10):946-51. PubMed ID: 12370101
[TBL] [Abstract][Full Text] [Related]
24. Loss of the tyrosyl radical in mouse ribonucleotide reductase by (-)-epicatechin.
Schroeder P; Voevodskaya N; Klotz LO; Brenneisen P; Gräslund A; Sies H
Biochem Biophys Res Commun; 2005 Jan; 326(3):614-7. PubMed ID: 15596143
[TBL] [Abstract][Full Text] [Related]
25. New ribonucleotide reductase inhibitors with antineoplastic activity.
Elford HL; Wampler GL; van't Riet B
Cancer Res; 1979 Mar; 39(3):844-51. PubMed ID: 427774
[No Abstract] [Full Text] [Related]
26. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Satyamoorthy K; Deshpande SS; Chitnis MP
Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
[TBL] [Abstract][Full Text] [Related]
27. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.
Szekeres T; Gharehbaghi K; Fritzer M; Woody M; Srivastava A; van't Riet B; Jayaram HN; Elford HL
Cancer Chemother Pharmacol; 1994; 34(1):63-6. PubMed ID: 8174204
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.
Cory JG; Carter GL; Bacon PE; T'ang A; Lien EJ
Biochem Pharmacol; 1985 Aug; 34(15):2645-50. PubMed ID: 3893440
[TBL] [Abstract][Full Text] [Related]
29. [Effect of nitrosomethylurea (NMU) on the growth kinetics and protein biosynthesis in leukemia L1210 cells].
Kukushkina GV; Sokolova IS; Ostrovskaia LA; Gorbacheva LB
Izv Akad Nauk SSSR Biol; 1972; 5():731-6. PubMed ID: 4667390
[No Abstract] [Full Text] [Related]
30. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of free ribonucleotide pool in the spleens of C57BL and DBA/2 mice and in leukemia cells sensitive and resistant to 5-fluorouracil].
Gerasimova GK; Mokina VD; Sidorova TA
Biokhimiia; 1978 Jan; 43(1):163-9. PubMed ID: 623843
[TBL] [Abstract][Full Text] [Related]
32. [Paramagnetic form of ribonucleotide reductase in human tissues].
Orazvalieva DR; Stepanov SV; Burgova EN; Zorina NI; Vanin AF
Biofizika; 1989; 34(1):139-40. PubMed ID: 2543465
[TBL] [Abstract][Full Text] [Related]
33. Murine splenocyte migration inhibition assay I. Detection of differential responses to murine leukemia P388 and its adriamycin-resistant subline P388/ADR.
Nori M; Gothoskar BP
Neoplasma; 1983; 30(3):287-93. PubMed ID: 6223231
[TBL] [Abstract][Full Text] [Related]
34. [Changes in the replication apparatus and phosphorus-containing metabolite pool in experimental tumors in animals during development].
Gorbacheva LB; Gudtsova KV; Dederer LIu; Sokolova IS; Sibel'dina LA; Shkarin PIu
Vopr Med Khim; 1991; 37(6):33-6. PubMed ID: 1812611
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.
Choy BK; McClarty GA; Chan AK; Thelander L; Wright JA
Cancer Res; 1988 Apr; 48(8):2029-35. PubMed ID: 2832057
[TBL] [Abstract][Full Text] [Related]
36. Response of transplantable tumors in mice and of macromolecular synthesis to 17 beta-acetamido-3-aza-A-homo-4 alpha-androsten-4-one.
Athanasiou C; Catsoulacos P; Papageorgiou A; Athanasiou K
Cancer Invest; 1987; 5(4):301-7. PubMed ID: 3664333
[TBL] [Abstract][Full Text] [Related]
37. Effects of N-hydroxy-N'-aminoguanidine derivatives on ribonucleotide reductase activity, nucleic acid synthesis, clonogenicity, and cell cycle of L1210 cells.
Weckbecker G; Weckbecker A; Lien EJ; Cory JG
Cancer Res; 1987 Feb; 47(4):975-8. PubMed ID: 2433036
[TBL] [Abstract][Full Text] [Related]
38. [Modulation of the antitumor activity of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosoure a by O(6)-methyl-2'-deoxyguanosine--a new inhibitor of O(6)-alkylguanine-DNA-alkyltransferase].
Dederer LIu; Sokolova IS; Bakhmedova AA; Miniker TD; Mel'nik SIa; Gorbacheva LB
Biokhimiia; 1995 Sep; 60(9):1521-9. PubMed ID: 8562657
[TBL] [Abstract][Full Text] [Related]
39. [Non-phosphorylative transglycosylation in the serum and liver of mice with transplantable leukemia P388 and L1210].
Sobiech KA; Madej JA; Kotoński B
Pol Arch Weter; 1986; 26(3-4):49-58. PubMed ID: 3438186
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of ribonucleotide reductase by antitumor agents related to levodopa and dopamine.
FitzGerald GB; Wick MM
Biochem Pharmacol; 1985 Feb; 34(3):353-60. PubMed ID: 3882092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
